CN111499559A - Method for synthesizing donepezil in water - Google Patents

Method for synthesizing donepezil in water Download PDF

Info

Publication number
CN111499559A
CN111499559A CN201910094515.5A CN201910094515A CN111499559A CN 111499559 A CN111499559 A CN 111499559A CN 201910094515 A CN201910094515 A CN 201910094515A CN 111499559 A CN111499559 A CN 111499559A
Authority
CN
China
Prior art keywords
reaction
donepezil
water
benzyl
iridium catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910094515.5A
Other languages
Chinese (zh)
Other versions
CN111499559B (en
Inventor
李峰
胥婧
孟冲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing University of Science and Technology
Original Assignee
Nanjing University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing University of Science and Technology filed Critical Nanjing University of Science and Technology
Priority to CN201910094515.5A priority Critical patent/CN111499559B/en
Publication of CN111499559A publication Critical patent/CN111499559A/en
Application granted granted Critical
Publication of CN111499559B publication Critical patent/CN111499559B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • B01J31/2282Unsaturated compounds used as ligands
    • B01J31/2295Cyclic compounds, e.g. cyclopentadienyls

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention discloses a method for synthesizing donepezil, which comprises the steps of adding 5, 6-dimethoxy indanone, 1-benzyl-4-piperidine methanol, a metal iridium catalyst and potassium hydroxide into a reaction container, heating for reacting for several hours, cooling to room temperature, spin-drying the solvent, and separating by a column to obtain a target compound. The method is characterized in that under the catalytic action of a metal iridium catalyst, 5, 6-dimethoxy indanone and 1-benzyl-4-piperidine methanol react to directly synthesize donepezil, raw materials used in the reaction are commercial reagents, and alcohol is an environment-friendly and low-toxicity chemical reagent; water produced by the reaction is a byproduct, so that the environment pollution is avoided; the atom economy of the reaction is high; the reaction was carried out in water. Therefore, the reaction meets the requirement of green chemistry and has wide development prospect.

Description

Method for synthesizing donepezil in water
Technical Field
The invention belongs to the technical field of organic drug synthesis, and particularly relates to a method for synthesizing donepezil.
Background
Donepezil (donepezil) is a long-acting symptomatic treatment of Alzheimer's Disease (AD). AD is an acquired mental decline with impairment of other cognitive functions, primarily manifested as memory decline. Donepezil is a second-generation cholinesterase (ChE) inhibitor whose therapeutic effect is to reversibly inhibit acetylcholinesterase (AchE) induced hydrolysis of acetylcholinesterase to increase acetylcholine content at the receptor site. Donepezil may have other mechanisms including direct action on peptide disposition, neurotransmitter receptors, or Ca2+ channels. Donepezil is suitable for mild and moderate dementia of the alzheimer type. Although the synthesis of donepezil has been developed, the original reports that the synthesis method uses toxic chemical reagents, multiple organic reactions, low atom economy and environmental pollution.
Disclosure of Invention
The invention aims to provide a method for synthesizing donepezil (donepezil).
The invention is realized by the following technical scheme: synthesis of donepezil (formula I)
Figure BDA0001964188470000011
Is prepared from 5, 6-dimethoxyindanone (formula II)
Figure BDA0001964188470000012
With 1-benzyl-4-piperidinemethanol (III) in the presence of an iridium complex and a base
Figure BDA0001964188470000013
Alkylation reaction in water.
The reaction formula is
Figure BDA0001964188470000021
The synthesis of donepezil by the invention is realized by the following specific steps:
adding 5, 6-dimethoxy indanone (formula II), 1-benzyl-4-piperidine methanol (III), a metal iridium catalyst and potassium hydroxide into a reaction vessel, heating for reacting for several hours, cooling to room temperature, spin-drying the solvent, and separating by a column to obtain the target compound.
The catalyst used in the invention is water-soluble metallic iridium catalyst [ Cp Ir (6,6- (OH)2bpy)(H2O)][OTf]2Or [ (CpIrCl)2(thbpym)][Cl]2The structure is as follows:
Figure BDA0001964188470000022
the iridium catalyst was used in an amount of 1mol Ir% relative to 5, 6-dimethoxyindanone, 5, 6-dimethoxyindanone relative to 1-benzyl-4-piperidinemethanol relative to 1.3equiv., and the base was used in a molar amount relative to 1-benzyl-4-piperidinemethanol of 1equiv.
Compared with the prior art, the preparation method disclosed by the invention has the advantages that the 5, 6-dimethoxy indanone (formula II) and the 1-benzyl-4-piperidine methanol are reacted under the catalytic action of the metallic iridium catalyst in the synthesis of donepezil, and the reaction is directly synthesized, and the reaction shows remarkable advantages: 1) the raw materials used in the reaction are commercial reagents, and the alcohol is an environment-friendly and low-toxicity chemical reagent; 2) water produced by the reaction is a byproduct, so that the environment pollution is avoided; 3) the atom economy of the reaction is high; 4) therefore, the reaction meets the requirement of green chemistry and has wide development prospect.
Detailed Description
The following examples are shown to illustrate certain embodiments of the present invention and should not be construed as limiting the scope of the invention. Many modifications, variations and changes in materials, methods and reaction conditions may be made simultaneously with respect to the disclosure herein. All such modifications, variations and changes are intended to fall within the spirit and scope of the present invention.
Example 1:
mixing 1-benzyl-4-piperidinemethanol (103mg,0.5mmol), 5, 6-dimethoxy indenone (125mg,0.65mmol,1.3equiv), [ Cp X Ir (6,6- (OH)2bpy)(H2O)][OTf]2(2.5mg,0.0025mmol,0.5 mol%), potassium hydroxide (28mg,0.5mmol,1equiv) and water (1m L) were added sequentially to the dried 25m L reaction mixture, reacted at 130 ℃ for 12 hours, cooled to room temperature, the solvent was removed by rotary evaporation, and then the pure target compound was obtained by column chromatography (developer: petroleum ether/ethyl acetate) with a yield of 80%.1H NMR(500MHz,DMSO-d6)7.33-7.25(m,4H,ArH),7.25-7.19(m,1H,ArH),7.04(s,2H,ArH),3.84(s,3H,CH3),3.77(s,3H,CH3),3.41(s,2H,CH2),3.17(dd,J=17.6Hz and 7.9Hz,1H,CH),2.77(t,J=12.5Hz,2H,CH2),2.64-2.56(m,2H,CH2),1.92-1.83(m,2H,CH2),1.73-1.64(m,2H,CH2),1.57(d,J=12.7Hz,1H,CH),1.46-1.33(m,1H,CH),1.24-1.16(m,2H,CH2),1.15-1.07(m,1H,CH);13C NMR(125MHz,DMSO-d6)206.6,155.2,149.1,148.7,138.6,128.7,128.4,128.1,126.8,108.1,103.8,62.5,55.9,55.5,53.3,44.8,38.3,33.9,32.7,31.4.。
Example 2:
except using [ (CpIrCl)2(thbpym)][Cl]2(2.5mg,0.0025mmol,1mol Ir%) instead of [ Cp Ir (6,6- (OH)2bpy)(H2O)][OTf]2Other reaction raw materials, conditions and products are the same as example 1, yield: 82.

Claims (6)

1. a method for synthesizing donepezil I in water, which comprises
Figure FDA0001964188460000011
The synthesis of the compound is carried out by 5, 6-dimethoxy indanone II,
Figure FDA0001964188460000012
with 1-benzyl-4-piperidinemethanol III in the presence of an iridium complex catalyst and a base
Figure FDA0001964188460000013
A step of preparing a target product by alkylation reaction in water,
Figure FDA0001964188460000014
2. the method of claim 1, wherein the iridium complex is a water-soluble metal-ligand bifunctional iridium catalyst having the following structure:
Figure FDA0001964188460000015
3. the process according to claim 1, wherein the iridium complex catalyst is used in an amount of 1mol Ir% relative to the 5, 6-dimethoxyindanone.
4. The method of claim 1, wherein the amount of 1-benzyl-4-piperidinemethanol is 1.3equiv. relative to 5, 6-dimethoxyindanone.
5. The process according to claim 1, wherein the molar amount of the base is 1equiv. relative to the molar amount of 5, 6-dimethoxyindanone.
6. The method of claim 1, wherein the base is potassium hydroxide.
CN201910094515.5A 2019-01-31 2019-01-31 Method for synthesizing donepezil in water Active CN111499559B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910094515.5A CN111499559B (en) 2019-01-31 2019-01-31 Method for synthesizing donepezil in water

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910094515.5A CN111499559B (en) 2019-01-31 2019-01-31 Method for synthesizing donepezil in water

Publications (2)

Publication Number Publication Date
CN111499559A true CN111499559A (en) 2020-08-07
CN111499559B CN111499559B (en) 2022-03-15

Family

ID=71867010

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910094515.5A Active CN111499559B (en) 2019-01-31 2019-01-31 Method for synthesizing donepezil in water

Country Status (1)

Country Link
CN (1) CN111499559B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702078A (en) * 2012-05-29 2012-10-03 扬子江药业集团江苏海慈生物药业有限公司 Method for preparing donepezil hydrochloride
CN107778217A (en) * 2016-08-29 2018-03-09 南京理工大学 Method for synthesizing donepezil
CN107903204A (en) * 2017-12-05 2018-04-13 郑州大学 A kind of synthetic method of donepezil

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702078A (en) * 2012-05-29 2012-10-03 扬子江药业集团江苏海慈生物药业有限公司 Method for preparing donepezil hydrochloride
CN107778217A (en) * 2016-08-29 2018-03-09 南京理工大学 Method for synthesizing donepezil
CN107903204A (en) * 2017-12-05 2018-04-13 郑州大学 A kind of synthetic method of donepezil

Also Published As

Publication number Publication date
CN111499559B (en) 2022-03-15

Similar Documents

Publication Publication Date Title
CN111943929B (en) 2,4-diaminopyridine nitroxides as catalysts and their use in the ring opening of azlactone alcohols
CN111499559B (en) Method for synthesizing donepezil in water
CN105001098B (en) A kind of preparation method of 3 (R)/(S)-amino-n-butyl alcohol
CN111138285A (en) Method for synthesizing organic carbonate from carbon dioxide, alcohol and brominated alkanes under mild condition
CN108467408B (en) Diaryl phosphorus compound with hydroxyphenyl functional group and preparation method thereof
CN113999125B (en) Preparation method of 2-methoxyethylamine
CN113788777B (en) Method for preparing 1-substituted-3-carbonyl pyrrole
CN113214104B (en) Method for synthesizing aromatic acetamide
CN112898152B (en) Preparation method of ethoxy diethyl methylene malonate
CN110734354B (en) Method for preparing biaryl compound from alcohol compound
CN114671910A (en) Green synthesis method of cidofovir
CN108727179B (en) Synthetic method of alpha-allyl substituted alpha, beta-unsaturated ketone, ester or nitrile compound
CN111393338A (en) Dorphityl-d3Medicine and its preparing method
ZA200503239B (en) Process for production of an acetylenic compound
CN114773229B (en) 1,6 Diene compound and preparation method and application thereof
CN115246772B (en) Preparation method of isobutyryl methyl acetate
CN112409186B (en) Method for synthesizing N-methylaniline in water
WO2011072703A1 (en) Process for the preparation of o-desmethyl-venlafaxine and salts thereof
CN113511966B (en) Synthesis method of trifluoromethyl substituted dihydrophenanthrene compound
CN114315874B (en) Method for preparing tetra-substituted alkenyl borate derivative
CN115784889B (en) Method for preparing methyl ethyl carbonate and diethyl carbonate by taking dimethyl oxalate as raw material
CN112321480B (en) Methylation synthesis method of N-heterocyclic compound
CN112811970B (en) Preparation method of 2-alkoxy-2-cyclopentene-1-ketone
CN111592451B (en) Preparation method of 4- (4-phenylbutoxy) benzoic acid
CN109384641B (en) Synthesis method of 1, 2-vicinal diol compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant